KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Gains from Investment Securities (2016 - 2025)

Biogen has reported Gains from Investment Securities over the past 17 years, most recently at $900000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $900000.0 for Q4 2025, down 99.1% from a year ago — trailing twelve months through Dec 2025 was $29.3 million (down 68.26% YoY), and the annual figure for FY2025 was -$19.3 million, down 510.64%.
  • Gains from Investment Securities for Q4 2025 was $900000.0 at Biogen, down from $5.6 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for BIIB hit a ceiling of $697.6 million in Q4 2021 and a floor of -$278.2 million in Q4 2023.
  • Median Gains from Investment Securities over the past 5 years was $5.6 million (2025), compared with a mean of $43.9 million.
  • Biggest five-year swings in Gains from Investment Securities: surged 4519.87% in 2021 and later tumbled 821.19% in 2023.
  • Biogen's Gains from Investment Securities stood at $697.6 million in 2021, then plummeted by 104.33% to -$30.2 million in 2022, then tumbled by 821.19% to -$278.2 million in 2023, then soared by 135.87% to $99.8 million in 2024, then tumbled by 99.1% to $900000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $900000.0 (Q4 2025), $5.6 million (Q3 2025), and $13.2 million (Q2 2025) per Business Quant data.